CHARLOTTE, N.C., Aug. 3, 2022 /PRNewswire/ — Albemarle Corporation (NYSE: ALB) today announced its results for the second quarter ended June 30, 2022. Second Quarter 2022 and Recent Highlights (Unless otherwise stated, all percentage changes represent year-over-year comparisons) Net…
Related Posts
Frontera Added To The S&P/TSX SmallCap Index
Frontera Added To The MSCI Canada Small Cap Index CALGARY, AB, June 1, 2022 /PRNewswire/ – Frontera Energy Corporation (TSX:…
Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg.
Pharma Desk, India: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ivabradine Tablets, 5 mg and 7.5 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Corlanor Tablets, 5…
Read More “Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg.” »
The post Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg. appeared first on NEWSX 360 : The Global News Platform.
Shanghai Futures Exchange and Shanghai International Energy Exchange release 2022 Q3 Trading Volume Statistics
SHANGHAI, Oct. 21, 2022 /PRNewswire/ — Shanghai Futures Exchange (SHFE) and its subsidiary Shanghai International Energy Exchange (INE) released trading…